Home β€Ί Healthcare β€Ί Drug Pipeline β€Ί Becker Muscular Dystrophy Pipeline Analysis 2018 (Q1) - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments

Becker Muscular Dystrophy Pipeline Analysis 2018 (Q1) - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments

πŸ“₯ Download Free SampleπŸ’¬ Speak to Analyst
$3,000
Single User License
Access Full Insights
Report OverviewSegmentationTable of ContentsCustomize Report

Report Overview

Becker Muscular Dystrophy Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Becker Muscular Dystrophy (BMD) Pipeline Analysis report covers 6 drugs currently in different phases of development. Becker muscular dystrophy is an X-linked recessive genetic disorder characterized by progressive weakness and wasting of the skeletal and cardiac muscles and is caused by is caused by a mutation in the DMD gene. This mutation that lead to a damaged "version" of dystrophin. Mutations that lead to an abnormal "version" of dystrophin that allow it to keep some of its function usually cause BMD. Muscle weakness often affects the legs and pelvis and gets worse with time leading to difficulty in walking, frequent falls and loss of muscle mass. It also affects cardiac muscles which may lead to cardiomyopathy. Laboratory tests such as Electromyography, Muscle biopsy or genetic testing and Creatine phosphokinase (CPK) are performed to diagnose the disease.
The report provides BMD treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Italfarmaco S.p.A and Cardero Therapeutics Inc. among others.
Scope:
 
By Company
By Phase
By Molecule Type
By Region
By Route of Administration

REPORT DETAILS

Report ID:KSI061611395
Published:Mar 2020
Pages:114
Format:PDF, Excel, PPT, Dashboard
πŸ“₯ Download SampleπŸ“ž Speak to AnalystπŸ“§ Request Customization

Need Assistance?

Our research team is available to answer your questions.

Contact Us

Frequently Asked Questions

The Becker Muscular Dystrophy Pipeline Analysis 2018 (Q1) - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments Market is expected to reach significant growth by 2030.

Key drivers include increasing demand across industries, technological advancements, favorable government policies, and growing awareness among end-users.

This report covers North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa with detailed country-level analysis.

This report provides analysis and forecasts from 2025 to 2030.

The report profiles leading companies operating in the market including major industry players and emerging competitors.

Related Reports

Healthcare

Hyperuricemia Treatment Market - Strategic Insights and Forecasts (2025-2030)

Jan 2026
Healthcare

Estrogen Blockers Market - Strategic Insights and Forecasts (2025-2030)

Jan 2026
Healthcare

Hormonal Contraceptives Market Size, Share, Opportunities, And Trends By Product Type (Oral Contraceptives, Injectable Contraceptive, Skin Patches, Intrauterine Devices (IUDs), Vaginal Rings, Emergency Contraceptive Pills), By Hormone Type (Progestin-Only Contraceptives, Combined Hormonal Contraceptives), By Distribution Channel, (Hospital, Retail, Online), And By Geography - Forecasts From 2025 To 2030

Jan 2025
Healthcare

Central Precocious Puberty (CPP) Treatment Market Size, Share, Opportunities, And Trends By Drug Type (Leuprorelin, Histrein, Triptorelin, Nafarelin), By Distribution Channel (Hospitals, Retail, Online), And By Geography - Forecasts From 2025 To 2030

Jan 2025
View All Reports